Navigation Links
Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research
Date:5/26/2010

Gavin MacBeath, Ph.D., will be responsible for leading the MM-121 research team through Development and creating the Company’s general strategy for predictive medicine.

(PRWEB) May 26, 2010 -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for cancer and inflammation, today announced that Gavin MacBeath, Ph.D., one of the Company’s six founders, has been hired as a Senior Director and the Head of Translational Research.

“Gavin joining Merrimack underscores the pivotal next step of our vision to extend Network Biology beyond discovery research and apply it to clinical development of drugs. We believe translational science anchored in Network Biology is a key recipe for developing next generation drugs as we better characterize the underlying tumor biology for the patients we are treating,” says Clet Niyikiza, Ph.D., Merrimack’s Senior Vice President of Development.

Since Merrimack was founded in 2000, Dr. MacBeath has served on the faculty in the Department of Chemistry and Chemical Biology at Harvard University, where he has focused on developing technology that facilitates basic research in the area of systems biology. In this new position, Dr. MacBeath will be responsible for leading the MM-121 research team through Development and creating the Company’s general strategy for predictive medicine.

“Merrimack provides the resources and environment needed to address what I believe is the biggest challenge in biomedical research for the twenty-first century - the problem of matching patients to therapies” said Dr. MacBeath. “Research and development at Merrimack over the coming years will determine how important Network Biology is in the context of co-developing drugs and companion diagnostics that identify which patients will respond most effectively.”

Dr. MacBeath will continue to direct a research lab at Harvard Medical School and will serve as a bridge between Merrimack and Harvard’s academic community. Dr. MacBeath received his Bachelors of Science at the University of Manitoba and his doctorate in Macromolecular and Cellular Structure and Chemistry at the Scripps Research Institute.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact: Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli(at)merrimackpharma(dot)com; Betsy Raymond Stevenson, 860-984-1424, RaymondStevenson Healthcare Comms betsy(at)raymondstevenson(dot)com

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb4048344.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
2. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
3. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
4. ARUP Laboratories CEO and Co-Founder Announces Retirement
5. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
6. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Scripps Research Institute Highlights Groundbreaking Work of aTyr Pharma Scientific Co-Founder
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
11. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research 
(Date:6/22/2017)... ... June 21, 2017 , ... Building on the success of the ... informative on the very latest developments in radical life extension. RAADfest combines cutting edge ... and the empowerment of personal development, making it the largest most comprehensive and inclusive ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... results to clients throughout the biopharma and life sciences industries, continue to be ... is seeing. Tunnell’s Kip Wolf will be speaking on “The State of Information ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... board of directors has formed a Higher Education Entrepreneurship Advisory Committee to implement ... institution presidents and other high-ranking representatives from 35 higher education institutions across the ...
(Date:6/20/2017)... ... 2017 , ... National executive search firm, Slone Partners, announces ... and biomarker expertise, as VP of Scientific Affairs at Cambridge Biomedical. , ... development and sample testing services. The organization acts as a leading provider of ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ... of online age and identity verification solutions, announced today ... Identity Conference 2017, May 15 thru May 17, 2017, ... Building and International Trade Center. Identity ... globe and in today,s quickly evolving digital world, defining ...
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
Breaking Biology News(10 mins):